PROJECT EVOLUTION

Projectevolution.org

Project Evolution's U.S. Advanced Therapies June 2022 Recap

In a Fast-Moving Industry, Stay Up-to-Date on the Happenings. Here is a Glimpse of Our Favorite Stories from June 2022.

Funding Updates:

- 06.02.22 - Upstream Bio Launches with $200M Series A Financing to Advance Novel Therapeutics for Allergic and Inflammatory Diseases (Press Release)
  - The funding will allow Upstream to advance the company's lead program UPB-101, a clinical-stage monoclonal antibody targeting the TSLP receptor, and build a pipeline of assets to address immune-mediated diseases. The Series A round was led jointly by OrbiMed and Maruho Co., Ltd. with participation from Access Biotechnology, Decheng Capital, HBM Healthcare Investments, TCG X, Omega Funds, Samsara BioCapital, and Altshuler Shaham Provident Funds Ltd. Upstream Bio acquired UPB-101 from Astellas following the successful completion of initial clinical and preclinical studies. Upstream has selected asthma as the first indication for UPB-101 with plans to pursue additional diseases driven by TSLP-mediated inflammation.
- 06.06.22 - ARCH-backed Resilience nabs its latest financing round, putting together a massive $625M Series D (Endpts)
  - Since emerging from stealth in late 2020, Resilience has methodically built up its cash reserves and inked numerous collaboration deals. On Monday, the company announced its latest move. The Bob Nelsen-backed biotech revealed plans for its Series D early Monday morning, putting together $625 million to further its mission of becoming the "Foxconn" of biotech. Monday's new cash will be used to continue investing in its infrastructure through more deals, potential acquisitions and R&D expansion.
- 06.07.22 - Vittoria Biotherapeutics—a Penn Spinoff—Secures $10m in Seed Financing while Emerging from Stealth Mode (Trialsitenews)
  - Based on intellectual property developed at University of Pennsylvania, Vittoria Biotherapeutics, a stealth mode gene therapy spinoff venture, secures $10 million in seed funding. Seeking to transcend the current limitations associated with CAR-T therapeutics, the company taps into proprietary novel cell engineering and gene editing technologies to develop therapies targeting unmet clinical needs.
- 06.07.22 - Code Bio corrals $75M to skip viruses, use synthetic DNA for genetic meds delivery (Medcitynews)
  - Code Biotherapeutics uses synthetic DNA as the foundation for its genetic medicines, which the startup claims offer several key advantages compared to genetic medicines delivered via engineered viruses. The startup plans to use its new capital to develop lead programs in Duchenne muscular dystrophy and type 1 diabetes.
- 06.14.22 - Dren Bio Announces $65 Million Series B Financing to Advance its Lead Asset into the Clinic and to Accelerate Development of New Product Candidates from its Targeted Myeloid Engager and Phagocytosis Platform (Press Release)
  - Momentum continues to build for Dren Bio after successfully forming highly experienced senior leadership team and earlier this year announcing research collaboration and license deal with Pfizer. The financing round was co-led by Aisling Capital and HBM Healthcare Investments with participation from new investors Pfizer, ArrowMark Partners, and Revelation Partners, along with all current insiders.
- 06.15.22 - CAMP4 Raises $45 Million to Usher in a New Era of Programmable Therapeutics to Upregulate Genes (Press Release)
  - announced that it has raised $45 million to propel the next phase of its scientific strategy, significantly expand its platform and advance multiple preclinical RNA therapies into human testing. CAMP4 is combining its proprietary RNA Actuating Platform (RAP) with state-of-the-art oligonucleotide technology to develop precise and programmable therapeutics that enable tunable upregulation of gene expression to treat disease. 5AM Ventures and Northpond Ventures led the financing alongside existing investors Andreessen Horowitz, Polaris Partners and The Kraft Group.
- 06.17.22 - Dilution be damned: Scholar Rock raises $205M as 24-month data point to durability of SMA efficacy (Fiercebiotech)
  - Stuck in a hard place, Scholar Rock has raised $205 million while its stock is at an all-time low to secure the cash it needs to survive through to the delivery of phase 3 spinal muscular atrophy (SMA) data. The biotech disclosed the financing alongside 24-month data from its phase 2 trial of apitegromab in SMA.
- 06.21.22 - Carbon Biosciences emerges with a new viral vector to shake up the cystic fibrosis gene therapy field (Endpts)
  - The Massachusetts biotech emerged Tuesday with $38 million in partnership with the Cystic Fibrosis Foundation to take a bocavirus-based gene therapy into the clinic for the lung disorder. The startup's first therapy, named CGT-001, can be delivered more than once, specifically targets the lung tissue and is able to transport the full-length cystic fibrosis gene. Carbon is based on science from John Engelhardt, director of University of Iowa's Center for Gene Therapy of Cystic Fibrosis, and Robert Kotin, professor of microbiology and physiological systems at University of Massachusetts Chan Medical School.

- 06.24.22 - Little-known OrbiMed-backed biotech closes $160M round to start gene therapy trial (Endpts)
  - Frontera Therapeutics, a China and US biotech, has closed a $160 million Series B and received regulatory clearance to test its first gene therapy stateside, Endpoints News has learned. Led by the largest shareholder, OrbiMed, the biotech has secured $195 million total since its September 2019 founding, according to an email reviewed by Endpoints. The lead AAV gene therapy program is for an undisclosed rare eye disease, according to the source. The startup has said little since its inception, aside from announcing a GMP manufacturing facility in Suzhou, China, which started construction in July 2021 and was launched in December of last year.
- 06.29.22 - ReCode Therapeutics to Expand Next-Generation Delivery Platform and Diversify Genetic Medicines Pipeline with Oversubscribed Series B Financing Totaling $200M (Press Release)
  - The Series B extension was co-led by AyurMaya, an affiliate of Matrix Capital Management, and Leaps by Bayer, with participation from Amgen Ventures. Adds to Existing Investors, including Pfizer Ventures, EcoR1 Capital and Sanofi Ventures. Proceeds to expand and diversify platform and pipeline to include mRNA and gene correction therapeutics for the central nervous system, lung, liver, and oncology indications.

Manufacturing Updates:

- 06.01.22 - Athenex Partners with Leading Contract Manufacturer GenScript ProBio in the Development of Advanced Cell and Gene Therapies (Press Release)
  - Over the past ten years, Athenex has established a productive relationship with GenScript and GenScript ProBio as a provider of high-quality reagents and materials to support multiple Research and Development initiatives. GenScript ProBio was launched in 2020 as a CDMO dedicated to the manufacturing of materials related to cell and gene therapy, vaccine, biologics discovery, and antibody protein drug. Athenex recognizes the continued potential of partnering with GenScript ProBio to support the cell therapy initiatives and leverage their existing affiliation.
- 06.02.22 - Vernal Biosciences Raises $21 Million to Accelerate mRNA Manufacturing Growth (Press Release)
  - Vernal Biosciences, a technology-leading mRNA manufacturer and formulator of LNP-mRNA, announced today the completion of a $21 million financing to fully integrate its mRNA manufacturing solutions. The round was led by Ampersand Capital Partners and Dynamk Capital, with existing investors Alloy Therapeutics and ATUM participating. The round also included a new investment from Charles River Laboratories, Inc. Vernal offers a complete range of mRNA-related services and products ranging from sequence design and screening support, scaled-down and scaled-up manufacturing of high purity mRNA and LNP-mRNA, platform process development technologies, and ultimately GMP manufacturing.
- 06.03.22 - With US Gov contract, Evonik ploughs $220m into Indiana lipid plant (Bioprocessinternational)
  - Evonik's lipid manufacturing facility in Lafayette, Indiana will service demand from the Biomedical Advanced Research and Development Authority (BARDA) for mRNA-based therapies beyond COVID-19 vaccines. Evonik's second largest site in the US will benefit from a lipid manufacturing facility. Construction is set to begin in early 2023, with the plant expected to be operational by 2025. Of the $220 million being invested in Tippecanoe, $150 million will come from the US Department of Health and Human Services (HHS) division BARDA to ensure supply of raw materials for mRNA vaccines.Around 80 new jobs will be added to the 650-large workforce at Tippecanoe.
- 06.06.22 - Resilience forges JV with MD Anderson, readying new cell therapies for cancer (Endpts)
  - The so-called Cell Therapy Manufacturing Center will be based in a 60,000SF facility in downtown Houston. With a team of 70 employees, the center will focus on process and analytical development as well as early-phase and clinical-stage GMP. The joint venture will look to combine MD Anderson's expertise in both immunotherapy and cell therapies, with Resilience's biomanufacturing technologies, advanced analytics, and their national network for developing and producing cell therapies. The parties aim to accelerate the path of cell therapies to the clinic while enabling scalability and a smooth transition to late-phase clinical and commercial activities.
- 06.07.22 -Astellas joins Pfizer in emerging North Carolina hub, unveiling new $100M gene therapy manufacturing site (Endpts)
  - The company's gene therapy branch, which came out of the acquisition of Audentes in 2019, has opened a new manufacturing facility in the city, comprising 135,000 square feet and shelling out $100 million. Astellas designed the site to provide clinical and commercial-scale manufacturing capabilities for its pipeline of AAV vectors for gene therapies, which includes programs from both Astellas's and Audentes's portfolios.The facility will also support global supply chain needs and in-house quality control testing, as well as the creation of more than 200 jobs through 2026. Currently, around 50 people are already employed at the site.
- 06.26.22 - Center for Breakthrough Medicines plans for an even larger dive into cell therapy manufacturing (Endpts)
  - The planning has begun on the manufacturing suites and supporting infrastructure, and when completed the facility, according to CBM's conservative calculations, the site will be able to produce around 10,000 batches of product per year in the space. In an email to Endpoints News, John Lee, VP and head of cell therapy at CBM, said its new one million square foot cell therapy expansion will include 90,000 square feet of GMP manufacturing space as well as offices and warehouse space. Lee also said that the facility's cost will be in the hundreds of millions, but no exact figure was given. Once completed, this will be one of the largest producers of cell therapy in the world.
- 06.27.22 - Ixaka and Minaris Regenerative Medicine Sign Tech Transfer and GMP Manufacturing Agreement for Lead Cell Therapy Candidate REX-001 (PRESS RELEASE)
  - REX-001 is an autologous multi-cell therapy (MCT) in development for the treatment of chronic limb-threatening ischemia (CLTI) in patients with diabetes. REX-001 is currently being evaluated in the randomized double-blind placebo controlled pivotal Phase 3 clinical trial (SALAMANDER trial) and the furthest advanced product in this indication

- 06.29.22 - Vedanta opens manufacturing facility to produce lead candidate as it heads for PhIII (Endpts)
  - Vedanta's new 7,000-square-foot facilities in Cambridge, MA, are designed to manufacture clinical and commercial supplies for its portfolio, including their oral c. difficile candidate VE303. The facility is an extension of the company's existing manufacturing capabilities and can produce multiple drug candidates, according to Vedanta. It also has CGMP capabilities to handle everything from clinical development to commercial launch. Manufacturing is expected to kick off in Q4 of this year. In October of 2021, positive Phase II results triggered a $23.8 million option from BARDA. The funds have been used to support the candidate in several capacities including manufacturing.
- 06.30.2022 - Fujifilm invests another $1.6B into its CDMO arm to upgrade facillites in the US and Europe (Endpts)
  - According to the company, it is further expanding its capacity to support large-scale cGMP-fed batch production by adding eight 20,000-liter bioreactors and two downstream processing streams at its Hillerød facility. The additional production capacity will make Hillerød one of the largest end-to-end CDMO facilities in Europe. The upgrades will offer a total of 20 20,000-liter bioreactors for drug substance production complemented by comprehensive drug products and finished goods services. For their site in the Lone Star State, the investment will expand cell culture manufacturing solutions by making use of their SymphonX and MaruX platforms to enable continuous processing.

Clinical & Approval Updates:

- 06.30.22 - Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update (Press Release)
  - To date, Talaris has enrolled 22 donor-recipient pairs in the Phase 3 FREEDOM-1 study (NCT# 03995901) of FCR001. Seven patients have been successfully dosed at five different trial sites. All three patients who were dosed more than 12 months prior to the data cutoff date have been successfully weaned off all chronic anti-rejection drugs without evidence of rejection and with stable kidney function. All of these patients, including the first patient who is now 24 months post-transplant, continue to remain off all anti-rejection drugs.
- 06.03.22 - Legend Biotech Announces U.S. FDA Clearance of IND Application for Solid Tumor. (Press Release)
  - CAR-T, LB1908 for Relapsed or Refractory Gastric, Esophageal and Pancreatic Cancers. (FDA) has cleared its IND application to evaluate LB1908 in Phase 1 clinical trial in the United States. LB1908 is an investigational, autologous chimeric antigen receptor T-cell (CAR-T) therapy.
- 06.08.22 - Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma (Press Release)
  - RMAT Designation Follows Positive Data from ALLO-501A ALPHA2 Trial in Heavily Pretreated Patients with Relapsed or Refractory Large B cell Lymphoma (LBCL). Data Presented at the American Society of Hematology (ASH) 2021 Annual Meeting Demonstrated AlloCAR T™ Could be Safe and Effective in Producing Durable Responses.
- 06.08.22 - Passage Bio Receives FDA Clearance of IND Application for PBML04 for Treatment of Metachromatic Leukodystrophy (Press Release)
  - The FDA has cleared its IND application for PBML04, a AAV-delivery gene therapy that is being studied for the treatment of Metachromatic Leukodystrophy (MLD). MLD is a rare, fatal, pediatric, lysosomal storage disease that currently has limited available treatment options.
- 06.28.22 - MeiraGTx Announces Positive Top-Line Data (Press Release)
  - The primary outcome of the MGT009 study is safety, and botaretigene sparoparvovec treatment was found to be generally safe and well-tolerated. Significant improvements were demonstrated in multiple different endpoints in botaretigene sparoparvovec-treated patients across each of the three domains of vision: retinal function, visual function, and functional vision. MeiraGTx and Janssen have a collaboration to develop and commercialize gene therapies for the treatment of inherited retinal diseases.
- 06.28.22 - XyloCor Therapeutics Achieves Target Enrollment in Phase 2 EXACT Study of XC001 Novel Gene Therapy for Ischemic Heart Disease (Press Release)
  - Achieved enrollment of the target number of subjects in the Phase 2 portion of its ongoing Phase 1/2 clinical trial (EXACT) for refractory angina. Topline results from the Phase 2 study are expected in February 2023 with interim results in the second half of this year.
- 06.24.22 - FDA Approves Bristol Myers Squibb's CAR T Cell Therapy Breyanzi® for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy (Press Release)
  - In the pivotal Phase 3 TRANSFORM trial, single infusion of Breyanzi significantly outperformed the nearly 30-year standard of care with median event-free survival of 10.1 months vs. 2.3 months and a well-established safety profile. Approval was also based on data from the Phase 2 PILOT study, the first and only company-sponsored study of a CAR T cell therapy in patients with primary refractory or relapsed LBCL who are not considered candidates for transplant, in which Breyanzi delivered deep and durable responses. With this approval, Breyanzi now has the broadest patient eligibility of any CAR T cell therapy in relapsed or refractory LBCL, reinforcing company's leadership in delivering innovative cancer treatments with Breyanzi as a cornerstone of its diversified cell therapy portfolio and pipeline

Collaboration & M&A Updates:

- 06.06.22 - Serotiny Announces a Research Collaboration With Janssen to Optimize Designs for Chimeric Antigen Receptors Signaling Domains (Press Release)
  - The collaboration will leverage Serotiny's tMDP mining and design capabilities with Janssen's antibody development and cell therapy expertise to create next generation CAR-based cell therapies that will potentially have improved therapeutic function and enhanced clinical benefit. The agreement was facilitated by Johnson & Johnson Innovation.

- 06.07.22 - Immatics and Editas partner on gene editing and T cells (Endpts)
  - Immatics and Editas Medicine announced Tuesday that they have entered into a research and licensing agreement. The deal will seek to combine gamma-delta T cell adoptive cell therapies and gene editing to develop medicines for cancer treatment. As part of the licensing agreement, Immatics gains non-exclusive rights to Editas Medicine's CRISPR technology and intellectual property. By combining Editas Medicine's gene editing technology with Immatics' cell therapy platform based on gamma-delta T cells, the latter can be redirected to cancer cell targets to create cells with enhanced tumor recognition and destruction, the companies said.
- 06.08.22 - Azenta to acquire Barkey Holding GmbH and its subsidiaries (Press Release)
  - Barkey is headquartered in Leopoldshöhe, Germany.Barkey has over four decades of expertise in the automated thawing of plasma, blood and stem cells and has more recently focused on cell and gene therapy (CGT) applications. Its key product lines are used for controlled rate thawing of cryopreserved samples and therapies. These products are used in R&D, clinical trials, GMP manufacturing and in hospitals. Barkey's plasmatherm product is an automated cell thawing device approved by the FDA as a medical device for clinical use.
- 06.08.22 - Integral Molecular and Optimeos Life Sciences Enter Partnership to Develop mRNA and DNA-Based Gene Therapies Using Molecular Targeting (Press Release)
  - Partnership to develop next-generation mRNA and DNA therapeutics that will use antibody-based molecular targeting to direct vaccines and gene therapies to relevant tissues in a patient's body. This partnership combines Integral Molecular's experience in antibody discovery and mRNA immunization with Optimeos' technology for nanoparticle-based drug delivery systems.
- 06.08.22 - The Parker Institute for Cancer Immunotherapy and Resilience Announce Strategic Alliance to Develop Next-Generation Cancer Therapies (Press Release)
  - The five-year collaboration aims to fund and spin out new companies based on discoveries from PICI's network of world-leading researchers and with access to Resilience's biomanufacturing technologies and capacity Together, PICI and Resilience aim to bring novel cell and gene therapies to market through the creation and incubation of new companies with a commitment of up to $50 million in funding. These startups will leverage groundbreaking technologies from across the PICI Network and have direct access to Resilience's biomanufacturing capacity, capability, and know-how.
- 06.15.22 - MIT-Northpond Program Created to Advance Innovation in Engineering and Life Science (Press Release)
  - MIT School of Engineering and Northpond Ventures today announced the launch of the MIT-Northpond Program – Advancing Life Science & Engineering Innovation. The five-year engagement is funded through Northpond Labs, the research and development-focused affiliate of Northpond Ventures. The program aims to generate ideas in the life sciences by connecting Northpond's experienced venture capital investors with MIT's scientific entrepreneurs, advancing commercialization through close mentorship and collaboration. Centered within the Department of Biological Engineering, the program will identify MIT researchers engaging in proof-of-concept research projects in the areas of diagnostics, R&D solutions, platforms for therapeutic solutions, biomanufacturing, and AI and software for treatment selection, all with the goal of commercializing their ideas
- 06.27.22- Alaunos Therapeutics and the National Cancer Institute Extend Cooperative Research and Development Agreement for Development of Personalized TCR-T Cell Therapies to 2025 (Press Release)
  - NCI will lead the Company's personalized TCR-T cell therapy program using the Company's proprietary non-viral Sleeping Beauty technology. Under the terms of the CRADA, the NCI will work to generate proof of concept utilizing the Company's proprietary non-viral Sleeping Beauty technology for personalized TCR-T cell therapy. In this setting, T-cell receptors (TCRs) that react to the patient's tumor will be identified from the patient and used to generate a TCR-T cell therapy. This approach could potentially apply to a wide range of solid tumor cancer patients.
- 06.27.22 - Trinity, St. James's and Legend Biotech: strategic collaboration explores solid tumours (Press Release)
  - Together, the entities will develop three-dimensional models exploring chimeric antigen receptor T-cell (CAR-T) cell therapies in solid tumours. CAR T-cell therapies are customized for each individual patient. They harness the body's own T cells and re-engineer them in the laboratory to produce proteins on their surface called chimeric antigen receptors, or CARs.
- 06.28.22 - Fate Therapeutics Announces Expansion of Solid Tumor Collaboration with ONO Pharmaceutical for Off-the-Shelf, iPSC-derived CAR NK and CAR T-Cell Cancer Immunotherapies (Press Release)
  - Expanded its off-the-shelf, iPSC-derived, cell-based cancer immunotherapy collaboration with ONO Pharmaceutical Co., Ltd. (ONO) to include the development of chimeric antigen receptor (CAR) NK cell collaboration candidates. In addition, as part of the collaboration's expansion, ONO will contribute novel binding domains targeting a second solid tumor antigen. Under the original Collaboration and Option Agreement entered into between Fate and ONO in September 2018, ONO has contributed novel binding domains targeting an initial solid tumor antigen, and Fate is currently conducting preclinical development of a multiplexed-engineered, iPSC-derived CAR T-cell product candidate for solid tumors.

Fund Rasing Updates:

- 06.04.22 - All in on early-stage, Qiming US bags $260M, recruits Atara founder Isaac Ciechanover for Fund III (Endpts)
  - Even as some of the public biotech companies in its portfolio bend under the weight of a bear market, Qiming Venture Partners USA is rolling up its sleeves to build more startups. The VC firm has taken the wraps off a $260 million third fund, dubbed US Healthcare Fund III, to execute on the same strategy as previous funds: invest in early-stage therapeutics and healthcare technology companies in the US and the EU.
- 06.09.22 - New Forbion life sciences fund hits €470M ($500M) Forbion Growth Opportunities Fund II. (LabBiotech.EU)
  - The fund will focus on investing in late-stage European life sciences companies. The new fund has attracted several new institutional investors, including pension funds PME and PMT, the Ewing Marion Kauffman Foundation and Reggeborgh, who join returning investors Pantheon, Wealth Management Partners and Eli Lilly and Company. The second fund will invest in mostly European, later-stage biopharma companies, developing novel therapies for areas of high medical need.

- 06.13.22 - Kairos Ventures Raises $58M Fund for Early-Stage Life Sciences Startups (DOT.LA)
  - a Beverly Hills-based venture capital was founded in 2015, the venture capital firm is known for backing physical and life sciences startups in their infancy, often as soon as they leave the university research labs in which they were incubated. Kairos initially focused on research coming out of Caltech, Chief Research and Development Officer Alex Andrianopoulos told dot.LA last year, but has since widened its scope to around a dozen other universities and has invested in more than 55 companies. Kairos also provides no-strings-attached grants, typically ranging between $100,000 to $200,000, to academic researchers, founder and CEO Jim Demetraides told the Wall Street Journal. That approach "builds relationships" between Kairos and those university-stage, would-be startups once they are ready for their first rounds of venture money, Demetraides said, with the venture firm having funded around 120 research programs to date, he told the Journal.Kairos previously raised $25 million for its first fund and $85 million for its second fund, according to PitchBook Data.
- 06.15.22 - Third Rock Ventures Raises $1.1 Billion Fund VI (Press Release)
  - Third Rock Ventures today announced the closing of Third Rock Ventures Fund VI, raising $1.1 billion. Fund VI will continue Third Rock's core strategy to discover, launch and build new groundbreaking companies focused on improving the lives of patients. Third Rock employs a hands-on approach to partnering with founders to build companies and provides early and rigorous integration of science, medicine, business and strategy to build successful companies. To date, Third Rock has raised $3.8 billion and its funds have invested in 60 companies. Importantly, companies across the portfolio have brought 18 products to the market across multiple therapeutic modalities and a broad range of disease indications including cancer, cardiovascular disease, depression, sickle cell disease, and rare genetic diseases among others. Fund VI is able to provide both initial Series A as well as follow-on capital to support companies throughout their lifecycle. Furthermore, Third Rock intends to allocate capital from Fund VI to invest in groundbreaking new companies from in the broader biotech ecosystem that are strongly aligned with Third Rock's mission and strategy.
- 06.29.22 - As bear market continues to beat down biotech, ARCH closes a $3B early-stage fund (Endpts)
  - ARCH Venture Partners closed its 12th venture fund early Wednesday morning, the firm said, bringing in almost $3 billion to invest in early-stage biotechs. The move comes about a year and a half after ARCH announced its previous fund, for almost $2 billion back in January 2021. In a statement, ARCH managing director and co-founder Bob Nelsen appeared to brush off concerns about the broader market troubles, alluding to the downturn that's seen several biotechs downsize and the XBI fall back to almost pre-pandemic levels. The firm hasn't finalized plans regarding the number of companies in which it plans to invest, but Nelsen said a "good guess" would be around 20 to 25 "core" companies with a bunch of smaller seed rounds as small as $50,000 included.
- 06.30.22 - Telegraph Hill Partners Raises $525M Fifth Fund for New Life Science and Healthcare Investments (Press Release)
  - THP V, a new $525 million investment fund. The fund will make investments in innovative companies that are commercializing advanced technologies in areas including life science tools, reagents, specialty chemistries, medical technology, medical devices, diagnostics, healthcare IT, healthcare services, agriculture and animal health.